JAGUAR HEALTH, INC. Income (Loss) from Equity Method Investments
JAGUAR HEALTH, INC. (JAGX) reported Income (Loss) from Equity Method Investments of -$36.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-19
- JAGUAR HEALTH, INC. income (loss) from equity method investments for the quarter ending 2026-06-30 was -$27.00K.
- JAGUAR HEALTH, INC. income (loss) from equity method investments for the quarter ending 2026-03-31 was -$9.00K.
- JAGUAR HEALTH, INC. income (loss) from equity method investments for the quarter ending 2025-12-31 was -$42.00K.
- JAGUAR HEALTH, INC. income (loss) from equity method investments for the quarter ending 2025-09-30 was -$45.00K.
- JAGUAR HEALTH, INC. income (loss) from equity method investments for fiscal 2025 was -$162.00K.
- JAGUAR HEALTH, INC. income (loss) from equity method investments for fiscal 2024 was -$138.00K.
- JAGUAR HEALTH, INC. income (loss) from equity method investments for fiscal 2023 was -$51.00K.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19 | -$36.00K 10-Q · filed 2026-08-19 | -$78.00K derived: sum of 3 quarters · filed 2026-08-19 | -$123.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$9.00K 10-Q · filed 2026-05-20 | -$51.00K derived: sum of 2 quarters · filed 2026-05-20 | -$96.00K derived: sum of 3 quarters · filed 2026-05-20 | -$138.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$87.00K derived: sum of 2 quarters · filed 2026-04-07 | -$129.00K derived: sum of 3 quarters · filed 2026-08-19 | -$162.00K 10-K · filed 2026-04-07 |
| 2025-09-30 | -$45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$87.00K derived: sum of 2 quarters · filed 2026-08-19 | -$120.00K 10-Q · filed 2025-11-14 | -$180.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-19 | -$75.00K 10-Q · filed 2026-08-19 | -$135.00K derived: sum of 3 quarters · filed 2026-08-19 | -$167.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$33.00K 10-Q · filed 2026-05-20 | -$93.00K derived: sum of 2 quarters · filed 2026-05-20 | -$125.00K derived: sum of 3 quarters · filed 2026-05-20 | -$155.00K derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-07 | -$92.00K derived: sum of 2 quarters · filed 2026-04-07 | -$122.00K derived: sum of 3 quarters · filed 2026-04-07 | -$138.00K 10-K · filed 2026-04-07 |
| 2024-09-30 | -$32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$62.00K derived: sum of 2 quarters · filed 2025-11-14 | -$78.00K 10-Q · filed 2025-11-14 | -$87.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$46.00K 10-Q · filed 2025-08-14 | -$55.00K derived: sum of 3 quarters · filed 2025-08-14 | -$60.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$16.00K 10-Q · filed 2025-05-15 | -$25.00K derived: sum of 2 quarters · filed 2025-05-15 | -$30.00K derived: sum of 3 quarters · filed 2025-05-15 | -$36.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$14.00K derived: sum of 2 quarters · filed 2025-03-31 | -$20.00K derived: sum of 3 quarters · filed 2025-03-31 | -$51.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$11.00K derived: sum of 2 quarters · filed 2024-11-13 | -$42.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$37.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$31.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |